However, the clinical potential of verteporfin in targeting YAP-TEAD driven cancers is limited as off-target effects have been reported, the cytotoxicity associated with verteporfin treatment having been shown as acting independently of YAP inhibition in a range of cancer cell models [218,219]. This evidence concerns the gene YAP1 and cancer.